What is the current stock price of GlucoTrack, Inc. (GCTK)?

As of the latest market data, GlucoTrack, Inc. (GCTK) is trading at $0.64. The stock has seen a gain of 7.13% today.

Does GlucoTrack, Inc. (GCTK) pay a dividend?

Based on current data, GlucoTrack, Inc. does not have a confirmed active dividend policy.

What is the market cap of GlucoTrack, Inc.?

The current market capitalization of GlucoTrack, Inc. (GCTK) is approximately unavailable.

GCTK

GlucoTrack, Inc.·Healthcare

0.64

7.131%(+0.04)

Close Price

0.69

8.320%(+0.05)

After Hours

Last Updated: — ET

52W L: $0.4352W H: $15.90

GCTK NEWS

globenewswire.com

1d ago

Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association's 2026 Scientific Sessions

RUTHERFORD, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that company leadership will present on its fully implantable continuous blood glucose monitoring (CBGM) technology at the American Diabetes Association's (ADA) 2026 Scientific Sessions, taking place in New Orleans, June 5 – 8, 2026.

globenewswire.com

May 14

Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology

globenewswire.com

May 7

Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology

Submission supports advancement of a long‑term, fully implantable, blood‑based continuous glucose monitoring platform Submission supports advancement of a long‑term, fully implantable, blood‑based continuous glucose monitoring platform

globenewswire.com

Apr 30

Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology

RUTHERFORD, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the publication of a peer reviewed scientific article in The Journal of Diabetes Research on the long-term accuracy and stability of the Company's fully implantable continuous blood glucose monitoring (CBGM) system in an in-vivo ovine model.

globenewswire.com

Apr 21

Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology

RUTHERFORD, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the publication of a peer-reviewed scientific article in the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal characterizing the long-term in-vitro stability of electrochemical glucose sensors of the type used in the Company's fully implantable continuous blood glucose monitoring (CBGM) system.

globenewswire.com

Mar 30

Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026

Company Profile

GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.

Sector

Healthcare

Industry

Medical - Instruments & Supplies

Employees

IPO Date

2013-04-25

Beta

0.72

Websitewww.glucotrack.com↗